# Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

> **NCT02216214** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 888 (actual)

## Conditions studied

- Overactive Bladder (OAB)

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02216214
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-07
- **Primary completion:** 2017-11-29
- **Final completion:** 2018-01-02
- **Target enrollment:** 888 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216214, "Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02216214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*